Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis

Schizophrenia Research

Volumn 169, Issue 1-3, 2015, Pages 204-208

  Schlosser, Danielle A ^a   Campellone, Timothy R ^a,b   Biagianti, Bruno ^a   Delucchi, Kevin L ^a   Gard, David E ^c   Fulford, Daniel ^d   Stuart, Barbara K ^a   Fisher, Melissa ^a,e   Loewy, Rachel L ^a   Vinogradov, Sophia ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO STATE UNIVERSITY   (United States)

^d BOSTON UNIVERSITY   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Experiential negative symptoms; Expressive negative symptoms; Motivation; Prodromal; Psychosis; Social functioning

Indexed keywords

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SOCIAL INTERACTION; SYMPTOM; ADOLESCENT; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM; PSYCHOLOGY; PSYCHOSIS; SOCIAL ADAPTATION; SOCIAL BEHAVIOR DISORDERS; STATISTICS; YOUNG ADULT;

ADOLESCENT; FEMALE; HUMANS; MALE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; RISK FACTORS; SOCIAL ADJUSTMENT; SOCIAL BEHAVIOR DISORDERS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84953727197     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.10.036     Document Type: Article

References (33)

1. Addington J., Cornblatt B.A., Cadenhead K.S., Cannon T.D., McGlashan T.H., Perkins D.O., Siedman L.J., Tsuang M.T., Walker E.F., Woods S.W., Heinssen R. At clinical high risk for psychosis: outcome for nonconverters. Am. J. Psychiatry 2011, 168:800-805.
2. Barch D.M. The relationships among cognition, motivation, and emotion in schizophrenia: how much and how little we know. Schizophr. Bull. 2005, 31:875-881.
3. Barch D.M., Dowd E.C. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr. Bull. 2010, 36:919-934.
4. Blanchard J.J., Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr. Bull. 2006, 32:238-245.
5. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., Seidman L.J., Perkins D., Tsuang M., McGlashan T., Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65:28-37.
6. Carbon M., Correll C.U. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014, 19(Suppl. 1):35-53.
7. Carrión R.E., Goldberg T.E., McLaughlin D., Auther A.M., Correll C.U., Cornblatt B.A. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am. J. Psychiatr. 2011, 168:806-813.
8. Cohen A.S., Minor K.S. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr. Bull. 2010, 36:143-150.
9. Cornblatt B.A., Auther A.M., Niendam T., Smith C.W., Zinberg J., Bearden C.E., Cannon T.D. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr. Bull. 2007, 33:688-702.
10. Cornblatt B.A., Carrion R.E., Addington J., Seidman L.J., Walker E., Cannon T.D., Cadenhead K., McGlashan T., Perkins D.O., Tsuang M., Woods S.W., Heinssen R., Lencz T. Risk factors for psychosis: impaired social and role functioning. Schizophr. Bull. 2012, 38:1247-1257.
11. Dowd E.C., Barch D.M. Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia. PLoS ONE 2012, 7.
12. Eslami A., Jahshan C., Cadenhead K.S. Disorganized symptoms and executive functioning predict impaired social functioning in subjects at risk for psychosis. J. Neuropsychiatr. Clin. Neurosci. 2011, 23:457-460.
13. Fervaha G., Foussias G., Agid O., Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophr. Res. 2015, 166(1-3):9-16.
14. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
15. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Agid O., Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr. Res. 2011, 132:24-27.
16. Fulford D., Niendam T.A., Floyd E.G., Carter C.S., Mathalon D.H., Vinogradov S., Stuart B.K., Loewy R.L. Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms. Schizophr. Res. 2013, 147:125-131.
17. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., Barale, Caverzasi E., McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:220-229.
18. Gard D.E., Fisher M., Garrett C., Genevsky A., Vinogradov S. Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr. Res. 2009, 115:74-81.
19. Green M.F., Hellemann G., Horan W.P., Lee J., Wynn J.K. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch. Gen. Psychiatry 2012, 69:1216-1224.
20. Kopelozicz A., Ventura J., Liberman R.P., Mintz J. Consistency of brief psychiatric rating scale factor structure across a broad spectrum of schizophrenia patients. Psychopatholoy 2008, 41(2):77-84.
21. Kring A.M., Gur R., Blanchard J., Horan W.P., Reise S. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am. J. Psychiatr. 2013, 170:165-172.
22. Meyer E.C., Carrion R.E., Cornblatt B.A., Addington J., Cadenhead K.S., Cannon T.D., McGlashan T.H., Perkins D.O., Tsuang M.T., Walker E.F., Woods S.W., Heinssen R., Seidman The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. Schizophr. Bull. 2014, 40:1452-1461.
23. Miller T.J., McGlashan T.H., Rosen J.L., Somjee L., Markovich P.J., Stein K., Woods S.W. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatr. 2002, 159:863-865.
24. Nelson B., Yuen H.P., Wood S.J., Lin A., Spiliotacopoulos D., Bruxner A., Broussard C., Simmons M., Foley D.L., Brewer W.J., Francey S.M., Amminger G.P., Thompson A., McGorry P.D., Yung A.R. Long-term follow-up of a group at ultra high risk ('prodromal') for psychosis: the PACE 400 study. JAMA Psychiatry 2013, 70:793-802.
25. Perivoliotis D., Morrison A.P., Grant P.M., French P., Beck A.T. Negative performance beliefs and negative symptoms in individuals at ultra-high risk of psychosis: a preliminary study. Psychopathology 2009, 42:375-379.
26. Piskulic D., Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Heinssen R., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., Woods S.W., McGlashan T.H. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012, 196:220-224.
27. Rassovsky Y., Horan W.P., Lee J., Sergi M.J., Green M.F. Pathways between early visual processing and functional outcome in schizophrenia. Psychol. Med. 2011, 41:487-497.
28. Schlosser D.A., Jacobson S., Chen Q., Sugar C.A., Niendam T.A., Bearden C.E., Cannon T.D. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr. Bull. 2012, 38:1225-1233.
29. Schlosser D.A., Fisher M., Gard D., Fulford D., Loewy R.L., Vinogradov S. Motivational deficits in individuals at-risk for psychosis and across the course of schizophrenia. Schizophr. Res. 2014, 158:52-57.
30. Velthorst E., Koeter M., van der Gaag M., Nieman D.H., Fett A.K., Smit F., Staring A.B., Meijer C., de Haan L. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol. Med. 2014, 1-13.
31. Woolley J.D., Fussel C., Chuang B., Biagianti B., Fulford D., Mathalon D.H., Vinogradov S. Intranasal oxytocin increases facial expressivity in patients with schizophrenia and healthy controls. Biol. Psychiatry 2015, (under review).
32. Wotruba D., Heekeren K., Michels L., Buechler R., Simon J.J., Theodoridou A., Kollias S., Rossler W., Kaiser S. Symptom dimensions are associated with reward processing in unmedicated persons at risk for psychosis. Front. Behav. Neurosci. 2014, 8:382.
33. Wykes T., Steel C., Everitt B., Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 2008, 34(3):523-537.